Day One Biopharmaceuticals Inc (DAWN)

Feb 26, 2025, 7:02 AM EST - 11 days ago

Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript

Feb 25, 2025, 4:05 PM EST - 11 days ago

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Feb 11, 2025, 8:30 AM EST - 26 days ago

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Jan 7, 2025, 11:31 AM EST - 2 months ago

Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)

Dec 25, 2024, 7:31 AM EST - 2 months ago

Day One Biopharmaceuticals: Sales Figures In The Crosshairs

Dec 17, 2024, 8:30 AM EST - 2 months ago

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 20, 2024, 4:30 PM EST - 3 months ago

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Nov 18, 2024, 8:30 AM EST - 3 months ago

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

Oct 30, 2024, 10:57 PM EDT - 4 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 4:01 PM EDT - 4 months ago

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

Oct 16, 2024, 8:30 AM EDT - 5 months ago

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

Jul 30, 2024, 7:30 AM EDT - 7 months ago

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

Jul 30, 2024, 7:00 AM EDT - 7 months ago

Day One Announces Oversubscribed $175.0 Million Private Placement

Jul 25, 2024, 12:58 AM EDT - 8 months ago

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

Jun 18, 2024, 8:30 AM EDT - 9 months ago

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

May 30, 2024, 8:30 AM EDT - 10 months ago

Day One Announces Sale of Priority Review Voucher for $108 Million

May 6, 2024, 4:30 PM EDT - 10 months ago

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

Apr 23, 2024, 3:56 PM EDT - 11 months ago

Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Feb 26, 2024, 4:30 PM EST - 1 year ago

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

Feb 1, 2024, 10:07 AM EST - 1 year ago

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

Dec 19, 2023, 8:00 AM EST - 1 year ago

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nov 17, 2023, 7:00 AM EST - 1 year ago

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

Nov 6, 2023, 4:30 PM EST - 1 year ago

Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

Oct 30, 2023, 8:00 AM EDT - 1 year ago

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Sep 15, 2023, 3:21 PM EDT - 1 year ago

Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch

Sep 11, 2023, 9:02 PM EDT - 1 year ago

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Aug 7, 2023, 4:30 PM EDT - 1 year ago

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

Jul 23, 2023, 4:43 AM EDT - 1 year ago

Diving Into Day One Biopharmaceuticals

Jun 12, 2023, 8:00 AM EDT - 1 year ago

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 6, 2023, 10:31 PM EDT - 1 year ago

Day One Announces Pricing of Public Offering of Common Stock

Jun 6, 2023, 4:01 PM EDT - 1 year ago

Day One Announces Proposed Public Offering of Common Stock

Jun 5, 2023, 10:59 AM EDT - 1 year ago

Cancer drugmakers rise as industry meet fuels investor interest

EVAX GTHX

Jun 5, 2023, 8:09 AM EDT - 1 year ago

Day One Biopharmaceuticals shares jump 23% on positive results for glioma treatment

Jun 4, 2023, 12:45 PM EDT - 1 year ago

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

May 30, 2023, 8:00 AM EDT - 1 year ago

Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference

May 25, 2023, 8:30 PM EDT - 1 year ago

CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023, 5:00 PM EDT - 1 year ago

Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 1, 2023, 9:00 AM EDT - 2 years ago

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

Apr 26, 2023, 9:31 AM EDT - 2 years ago

Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress

Apr 7, 2023, 7:37 AM EDT - 2 years ago

Day One Biopharmaceuticals: Strong Potential, Price Drop Opportunity, Some Concerns

Mar 6, 2023, 4:30 PM EST - 2 years ago

Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress

Feb 27, 2023, 8:00 AM EST - 2 years ago

Day One to Participate in the Cowen 43rd Annual Health Care Conference

Jan 9, 2023, 8:30 AM EST - 2 years ago

Day One to submit its glioma drug to the FDA this year

Jan 8, 2023, 5:00 PM EST - 2 years ago

Day One Announces Topline Data from Pivotal Phase 2 FIREFLY-1 Trial Demonstrating Meaningful Responses with Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma

Dec 20, 2022, 8:00 AM EST - 2 years ago

Day One to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 17, 2022, 7:00 AM EST - 2 years ago

Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nov 11, 2022, 7:00 AM EST - 2 years ago

Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting

Nov 7, 2022, 4:30 PM EST - 2 years ago

Day One Reports Third Quarter 2022 Financial Results and Corporate Progress

Oct 17, 2022, 8:00 AM EDT - 2 years ago

Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)